Federated Hermes
PDLI

Federated Hermes’s PDL BioPharma, Inc. PDLI Stock Holding History

Federated Hermes’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-360,775
Closed -$1.14M – 2428
2020
Q3 		$1.14M Sell
360,775
-61,294
-15% -$196K ﹤0.01% 1190
2020
Q2 		$1.23M Sell
422,069
-15,888
-4% -$50.2K ﹤0.01% 1176
2020
Q1 		$1.24M Sell
437,957
-98,112
-18% -$316K ﹤0.01% 1049
2019
Q4 		$1.74M Sell
536,069
-77,984
-13% -$226K ﹤0.01% 1071
2019
Q3 		$1.33M Sell
614,053
-15,559
-2% -$41.6K ﹤0.01% 1179
2019
Q2 		$1.98M Sell
629,612
-14,005
-2% -$45.4K ﹤0.01% 1057
2019
Q1 		$2.39M Sell
643,617
-98,827
-13% -$334K 0.01% 989
2018
Q4 		$2.15M Sell
742,444
-154,542
-17% -$425K 0.01% 1000
2018
Q3 		$2.36M Sell
896,986
-297,001
-25% -$729K 0.01% 1033
2018
Q2 		$2.79M Sell
1,193,987
-91,535
-7% -$256K 0.01% 881
2018
Q1 		$3.78M Sell
1,285,522
-218,188
-15% -$596K 0.01% 717
2017
Q4 		$4.12M Sell
1,503,710
-44,370
-3% -$136K 0.01% 672
2017
Q3 		$5.25M Buy
1,548,080
+102,668
+7% +$285K 0.02% 557
2017
Q2 		$3.57M Buy
1,445,412
+74,559
+5% +$171K 0.01% 682
2017
Q1 		$3.11M Buy
1,370,853
+232,080
+20% +$513K 0.01% 734
2016
Q4 		$2.41M Buy
1,138,773
+217,315
+24% +$606K 0.01% 799
2016
Q3 		$3.09M Sell
921,458
-51,475
-5% -$163K 0.01% 698
2016
Q2 		$3.06M Buy
972,933
+36,888
+4% +$123K 0.01% 691
2016
Q1 		$3.12M Buy
936,045
+267,626
+40% +$834K 0.01% 674
2015
Q4 		$2.37M Buy
668,419
+343,001
+105% +$1.44M 0.01% 796
2015
Q3 		$1.64M Buy
325,418
+96,031
+42% +$550K 0.01% 941
2015
Q2 		$1.48M Buy
+229,387
New +$1.54M ﹤0.01% 1035
2015
Q1 		– Sell
-1,770,133
Closed -$13.6M – 2143
2014
Q4 		$13.6M Buy
1,770,133
+1,520
+0.1% +$12K 0.04% 370
2014
Q3 		$13.2M Buy
1,768,613
+790,904
+81% +$7.34M 0.04% 374
2014
Q2 		$9.46M Buy
977,709
+571,494
+141% +$5.09M 0.03% 470
2014
Q1 		$3.38M Buy
406,215
+398,393
+5,093% +$3.41M 0.01% 769
2013
Q4 		$66K Sell
7,822
-806
-9% -$6.79K ﹤0.01% 1635
2013
Q3 		$69K Sell
8,628
-5,955
-41% -$47.9K ﹤0.01% 1600
2013
Q2 		$113K Buy
+14,583
New +$114K ﹤0.01% 1512

Other funds holding PDLI

SPC
Silver Point Capital Greenwich, Connecticut $1.3B AUM 18.3% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
KBC Group
KBC Group Brussels, Belgium $39.9B AUM 29.7% 1-Year Est. Return
GCIA
Gabelli & Co Investment Advisers Rye, New York $674M AUM 64.52% 1-Year Est. Return
JC
JBF Capital Aspen, Colorado $676M AUM 24.74% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return
CCM
Context Capital Management Lajolla, California $4.33B AUM 1.35% 1-Year Est. Return
WG
Winton Group London, United Kingdom $2.85B AUM 30.73% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

Federated Hermes's PDLI Position: Q4 2020 in Review

Federated Hermes sold out of PDL BioPharma, Inc. (PDLI) in Q4 2020, closing a stake of 360,775 shares — an estimated $1.14M sold.

Federated Hermes first reported a position in PDLI in Q2 2013 and held it in 29 quarters. The position peaked at $13.6M in Q4 2014. 33 funds tracked by Wall St. Rank hold PDLI as of Q4 2020.

  • Federated Hermes reported no remaining PDL BioPharma, Inc. position as of Q4 2020 after selling out during the quarter.
  • Federated Hermes sold 360,775 PDL BioPharma, Inc. shares in Q4 2020, an estimated $1.14M.
  • Federated Hermes first reported a position in PDL BioPharma, Inc. in Q2 2013 and held it in 29 quarters.
  • Federated Hermes's PDL BioPharma, Inc. position peaked at $13.6M in Q4 2014.
  • 33 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q4 2020.

Based on Federated Hermes's 13F filing for Q4 2020, filed 12 Feb 2021.